Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

Published

Journal Article

We compared the prognostic value of liver biopsy (LB) and FIB-4 index in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection.We studied patients from the Grupo de Estudio del SIDA 3603 study cohort, in whom fibrosis was evaluated at baseline using both LB (Metavir score) and FIB-4 index. We assessed overall death (OD) and liver-related events (LREs), defined as decompensation or hepatocellular carcinoma, whichever occurred first. We used receiver operating characteristic (ROC) curves to determine the ability of LB and FIB-4 to predict outcomes. We also assessed the association between advanced fibrosis-LB (F3 or greater) or FIB-4 (≥3.25)-and outcomes using multivariate Cox regression analysis.The study sample comprised 903 patients (328 with sustained virologic response [SVR]). Baseline fibrosis by LB was as follows: F0, n = 71; F1, n = 242; F2, n = 236; F3, n = 236; F4, n = 118. Fibrosis by FIB-4 was as follows: ≤1, n = 148; >1 to <3.25, n = 597; ≥3.25, n = 158. After a median follow-up of 62 months, there were 46 deaths and 71 LREs. The area under the ROC curves for OD/LREs was 0.648 and 0.742 for LB and FIB-4, respectively (P = .006). Similar results were found for patients without SVR and for OD and LREs separately. The adjusted hazard ratios of OD or LRE were 1.740 (95% confidence interval [CI], 1.119-2.7.06; P = .014) for advanced fibrosis assessed by LB and 3.896 (95% CI, 2.463-6.160; P < .001) assessed by FIB-4.FIB-4 outperformed LB as a predictor of OD and LRE. These findings are of relevance for clinical practice and research and call into question the role of LB as a gold standard for assessing prognosis in HIV/HCV coinfection.

Full Text

Cited Authors

  • Berenguer, J; Zamora, FX; Aldámiz-Echevarría, T; Von Wichmann, MA; Crespo, M; López-Aldeguer, J; Carrero, A; Montes, M; Quereda, C; Téllez, MJ; Galindo, MJ; Sanz, J; Santos, I; Guardiola, JM; Barros, C; Ortega, E; Pulido, F; Rubio, R; Mallolas, J; Tural, C; Jusdado, JJ; Pérez, G; Díez, C; Álvarez-Pellicer, J; Esteban, H; Bellón, JM; González-García, J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group,

Published Date

  • March 2015

Published In

Volume / Issue

  • 60 / 6

Start / End Page

  • 950 - 958

PubMed ID

  • 25422386

Pubmed Central ID

  • 25422386

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

International Standard Serial Number (ISSN)

  • 1058-4838

Digital Object Identifier (DOI)

  • 10.1093/cid/ciu939

Language

  • eng